Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 234 for “"triple-negative"”.
-
Characterising pathways driving aggressive biology and chemoresistance in triple negative breast cancers biology and chemoresistance in triple negative breast cancers
This body of work served to investigate the mechanisms driving chemoresistance in a series of in vitro TNBC cell line models. Molecular characterisation and comparison of drug resistant models allowed for the identification of promising druggable targets, whose efficacy in restoring …
-
Tyrosine Kinase Inhibitors in Triple Negative Breast Cancer
Basal-like breast cancers are generally negative for estrogen and progesterone receptor expression and HER-2 amplification (‘triple negative’ breast cancer, TNBC), and express basal cytokeratins 5/6, and EGFR (epidermal growth factor receptor). No targeted therapy options are currently approved for …
-
Mechanism of metastasis of triple negative breast cancer
Triple Negative Breast Cancer (TNBC) is increasingly recognised as a serious, worldwide public health concern. TNBC has the ability to recur after treatment and appears to be greatest in the first few years. The phenotypical changes of the TNBC metastasis represent a unique that heterogeneous …
-
Engineering multimodal nanoparticles to combat triple-negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype of cancer that accounts for about 15-20% of all breast cancer cases and has a poorer short-term prognosis when compared to other subtypes. Many current chemotherapeutics used to treat TNBC are nonspecific, and, therefore, cause …
-
Engineering therapeutic messenger RNA for triple-negative breast cancer
… treatments (15-30% of breast cancers). Triple-negative breast cancer (TNBC) is characterised by the absence of HER2 and hormone receptors. TNBC is an aggressive subset of breast cancers for which few targeted therapies are available. It has recently been shown that artificial …
-
NANOPARTICLE BASED MULTI-MODAL THERAPIES AGAINST TRIPLE-NEGATIVE BREAST CANCER
Triple-negative breast cancer (TNBC) is a highly metastatic and lethal form of breast cancer that lacks surface markers commonly targeted by hormone or immunotherapies. Silver nanoparticles (AgNPs) have exhibited a selective toxicity against TNBC cell lines at concentrations that are not lethal to …
-
Development Of Recombinant Immunotherapeutics for Triple-Negative Breast Cancer (TNBC)
… are several subtypes of breast cancers including Triple-negative breast cancer (TNBC), which is mainly characterized by a lack of expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). TNBC is one of the most aggressive subtypes of …
-
A Screen For Peptides Targeting Chemoresistant Metastatic Triple-Negative Breast Cancer
… progression. This is often the case in triple-negative breast cancer (TNBC), an aggressive breast cancer subtype where tumorigenesis is independent of HER-2, progesterone, or estrogen receptor expression. Despite improving TNBC prognosis, recent studies report that after chemotherapy …
-
rRNA transcription as potential therapeutic target in triple negative breast cancers
Cancer has been identified as a group of diseases characterized by abnormal cell growth. In eukaryotic cells, the nucleolus is the region of the nucleus where initial stages of ribosome production occur. These stages include synthesis of ribosomal RNAs by RNA Polymerase 1 (RNAP1) followed by its …
-
Identifying Oncogenic Drivers of Poor Outcome in Triple Negative Breast Cancer
Triple Negative Breast cancers (TNBC) are defined by an absence of HER2 amplification, and a lack of estrogen (ER) and progesterone (PR) expression. They are an especially aggressive and poor prognosis subtype of Breast cancer and are associated with high incidence of chemoresistance and …
-
Investigating the transcriptional regulation of BCL11A in Triple-negative Breast Cancer
… aggressive subtype of breast cancer is called Triple-negative breast cancer (TNBC) and is clinically defined by the absence of the three receptors mentioned above. These TNBC patients have the poorest prognostic outcome among the subtypes and highest mortality rate due to the lack of targeted …
-
Astaxanthin Decreases Invasion and MMP Activity in Triple Negative Breast Cancer Cells
… was effective against invasion and metastasis of triple-negative breast cancer (TNBC) cells. We determined that Astaxanthin decreases invasion of 4T1 cells through Matrigel<sup>TM</sup>, but does not affect proliferation. Using zymography we showed that 4T1 cells treated with Astaxanthin …
-
Preclinical Development of Therapeutic Strategies Against Triple-Negative and Inflammatory Breast Cancer
<p>Triple-negative (TNBC) and inflammatory (IBC) breast cancer are the most aggressive forms of breast cancer, accounting for 20% and 10% of cancer-related deaths, respectively. Among IBC cases, 30% are additionally classified with TNBC molecular pathology, a diagnosis that significantly worsens …
-
Mir-484 Functions As An Onco-Mir In Triple Negative Breast Cancer
<p>Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer (BC), with a poor prognosis with currently used therapies, and thus represents an unmet therapeutic challenge. Lack of molecular targets (i.e. ER, PR, HER2) and significant genetic heterogeneity are the major …
-
Identification of novel biomarkers and therapeutic strategies in triple negative breast cancer
Triple negative breast cancer (TNBC) is a highly heterogeneous disease that accounts for around 15% of all breast cancers but is responsible for a disproportionately high rate of mortality. Characterised by lack of expression of the hormone receptors estrogen receptor α (ERα), progesterone receptor …
-
Development of Novel Peptide-Doxorubicin Conjugates for Targeting Triple-Negative Breast Cancer
<p>Triple-negative breast cancer (TNBC) is the most aggressive and difficult to treat subtype of breast cancer. Chemotherapy is an active treatment option in combination with other treatments; however, the side effects limit the effective therapeutic dose. To selectively target the cancer cells, I …
-
Investigation of anthracycline based topoisomerase II inhibitors in triple negative breast cancer
Triple negative breast cancer (TNBC) constitutes10-20% of all breast cancer (BCa) cases. TNBC remains unresponsive to targeted therapy, and primarily relies on chemotherapy for treatment. Mitoxantrone (MTX), a topoisomerase II inhibitor belonging to the anthracenedione class, is used in BCa …
-
Evaluating CD44-EZRIN Interactions in Triple-Negative Breast Cancer: Tumourigenesis and Drug Resistance
… Ezrin and CD44 in the engraftable MDA-MB-231 triple-negative breast cancer cell line model. We show that CD44 and Ezrin each play important roles in regulating cancer cell associated processes in vitro such as cell adhesion, clonogenic potential, directional migration, and sensitivity to …
Page 1 of 12